ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC)
Clinical trials for ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC) explained in plain language.
Never miss a new study
Get alerted when new ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC) trials appear
Sign up with your email to follow new studies for ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Rosacea redness gel shows promise in small study
Symptom relief CompletedThis study tested a gel called brimonidine on 45 adults with rosacea-related facial redness. In the first part, one side of the face got the gel and the other a placebo to see immediate effects. In the second part, everyone used the gel daily for a month. Redness was measured wit…
Matched conditions: ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC)
Phase: PHASE4 • Sponsor: Istanbul Training and Research Hospital • Aim: Symptom relief
Last updated May 26, 2026 08:39 UTC
-
Can a nerve pain drug calm rosacea Flare-Ups?
Symptom relief CompletedThis study tested whether gabapentin, a drug usually used for nerve pain, can reduce facial redness and flushing in people with rosacea. Fifty adults with rosacea took either gabapentin or a standard treatment for 12 weeks. Researchers measured redness using a doctor-rated scale …
Matched conditions: ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC)
Phase: PHASE1 • Sponsor: First Affiliated Hospital of Chongqing Medical University • Aim: Symptom relief
Last updated May 19, 2026 11:48 UTC